Literature DB >> 31832978

The effectiveness of lifestyle interventions to reduce side effects of androgen deprivation therapy for men with prostate cancer: a systematic review.

Maud J M Geerkens1, Nieck S A Pouwels2, Harry P Beerlage2.   

Abstract

PURPOSE: The aim of this review is to systematically review randomized controlled trials on lifestyle interventions on PCa patients undergoing androgen deprivation therapy.
METHODS: A literature search was conducted using the electronic databases Medline and PubMed. To be eligible, studies had to be randomized controlled trials (RCTs) that focused on side effects of ADT and lifestyle interventions to reduce side effects for men undergoing ADT with PCa. Lifestyle interventions were defined as interventions that included any dietary or behavioral components.
RESULTS: Twenty-nine trials were included. Most of them focused on exercise interventions, while some investigated the effect of dietary or behavioral interventions. The effect of different lifestyle influencing modalities aimed to improve on the adverse effects of ADT varied greatly.
CONCLUSIONS: It is not possible to draw one conclusion on the effect of exercise-based interventions, but noted on several adverse effects of ADT improvement. Further studies are necessary to develop personalized lifestyle interventions in order to mitigate the adverse effects.

Entities:  

Keywords:  ADT; Lifestyle interventions; Males; Prostate cancer; Side effects

Mesh:

Substances:

Year:  2019        PMID: 31832978      PMCID: PMC7142057          DOI: 10.1007/s11136-019-02361-z

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


Introduction

Prostate cancer is one of the most common forms of cancer in men and the second cause of death [1]. Androgens and androgen receptor signaling play an important role in the normal growth and function of the prostate, but also in the development and maintenance of prostate cancer. The beneficial effect of castration in the treatment of prostate cancer has already been discovered in 1941, by Huggins [2]. LHRH agonists are the most chosen form of chemical castration [3]. LHRH agonists bring the serum testosterone to a level similar to castration by interfering in the pulsatile release of LHRH in the hypothalamus, thereby down-regulating the release of luteinizing hormone in the anterior pituitary gland. Androgen deprivation therapy (ADT) achieves a remission in 80–90% in men with advanced prostate cancer and an average progression-free interval of 12–33 months [4]. Despite the fact that this form of therapy is very successful, it also known for its side effects and the impact of these side effects on the quality of life in addition to the psychological and physical effects influencing the quality of life in the long term. The most common life quality diminishing side effects are reduced libido, depression, fatigue, gynecomastia, hot flushes, obesity, hypertension, insulin resistance, and osteoporosis [5]. Non-pharmaceutical lifestyle interventions aimed to reduce side effects while aiming to leave control in the hands of the patient are very important. They may prevent medicalization and are thought to increase quality of life. Previous reviews have shown that physical activity may alleviate side effects of ADT [6, 7]. These reviews mainly focused on the effects of different types of exercise, but did not include all types of lifestyle interventions. The aim of this research is to provide a comprehensive overview of recent physical and psychological lifestyle interventions to reduce different side effects of ADT and to investigate the impact of these interventions on quality of life.

Methods

Data acquisition and search strategy

A literature search was conducted using the electronic databases Medline and PubMed. The literature search included relevant publications until January 25, 2019. Predefined search terms were used to identify articles concerning interventions to reduce side effects of ADT used as a therapy for prostate cancer.

Eligibility criteria

To be eligible, the study population had to consist of patients diagnosed with local or advanced PCa in whom ADT was started. Studies had to be randomized controlled trials (RCTs) that focused on side effects of ADT and lifestyle interventions to reduce those side effects. For this review, we selected studies concerning the following psychological effects: quality of life (health-related quality of life and disease-specific quality of life), fatigue, reduced libido, and depression. We selected studies investigating the following physical side effects: gynecomastia, hot flushes, osteoporosis, obesity, or a decreased cardiovascular health. Lifestyle interventions were defined as interventions that included any dietary or behavioral components. Studies reporting on medical therapies to diminish side effects were excluded, as were studies in which the participants stopped their ADT and studies not related to humans.

Screening of abstracts and full-text articles

A search was performed for abstracts that may be used for inclusion. Abstract screening was done according to predefined inclusion and exclusion criteria. Full-text original articles were retrieved from the selected abstracts; only articles published in English or Dutch that were available for review were selected. Abstracts and original articles were independently assessed by two reviewers for eligibility (MG and NP). Disagreements were solved by consensus procedure in which an independent third author (HBLG) was conducted. Subsequently, reference lists of all full-text articles were screened to identify additional relevant articles not found in the PubMed and Medline databases. The final number of included and excluded studies is illustrated in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (Fig. 1).
Fig. 1

Flow chart of the search and selection process

Flow chart of the search and selection process

Study quality assessment tool

The Cochrane Collaboration’s tool was used to assess the risk of bias in the randomized controlled trial [8]. Two reviewers (MG and NP) assessed the overall quality. If no agreement could be reached, an independent person was involved (HPB).

Data synthesis

The following data were independently extracted from full-text articles by two reviewers: study year, study design, study population, mean age, type of interventions, duration and frequency of interventions, relevant study outcomes, and methods to assess these outcomes.

Results

Search results and analysis

Our literature search identified 1961 of which 29 articles were included in this analysis. The studies were all RCTs investigating the effect of life style interventions to mitigate ADT-induced side effects. Twenty studies investigated exercise modalities, two studies investigated dietary advice, and four studies combined these methods. Three studies investigated behavioral components, existing of cognitive behavioral therapy, educational support programs, or self-education. Study characteristics are depicted in Table 1.
Table 1

Study characteristics of the included studies

Study yearPatients (n)Age (mean)Inclusion criteriaInterventionsDuration intervention (weeks) + frequency (x/week)Relevant outcomesMethods to assess relevant outcomes
Segal [9]

Int: 82

Con: 73

Total: 155

Int: 68.2

Con: 67.7

Local and advanced

PCa receiving ADT ≥ 3 months

Supervised resistance exercise

Duration: 12

Frequency: 3

Fatigue

Overweight

Quality of life

FACT-F

BMI, waist circumference, skinfolds thickness

FACT-P

Taylor [10]

Life: 46

Educ: 51

Con: 37

Total: 134

Int + Con: 69.2PCa treated with ADT

Lifestyle activity program

Educational support program

Duration 24 Frequency: week 1–16: 1

4 week: 2

Overweight

Depression

Quality of life

BMI: Waist and hip circumferences, waist-hip ratio

CES-D

SF-36, STAI

Sharma [11]

Soy: 20

Con: 19

Total 39

Soy: 69.2

Con: 69.0

PCa treated with ADTSoy protein: 20 g

Duration: 12

Frequency: 7

Fatigue

Libido and sexual function

Hot flushes

Quality of life

SF-36

IIEF, WSFS

Blatt-Kupperman scale SF-36

Culos-Reed [12]

Int: 53

Con: 47

Total: 100

Int: 67.2

Con: 68

PCa localized or metastatic and expect to receive ADT for ≥ 6 monthsSupervised and unsupervised aerobic + resistant exercise

Duration: 16

Frequency: 3–5

Fatigue

Overweight

Cardiovascular Libido

Depression

Quality of life

FSS

BMI, waist-to-hip ratio

RR

EPIC

CES-D

EORTC-QLQ-C30, EPIC

Galvao [13]

Int: 29

Con: 28

Total: 57

Int: 69.5

Con: 70.1

Locally or advanced PCa (without bone metastasis) with prior exposure ADT > 2 monthsSupervised aerobic + resistance exercise

Duration: 12

Frequency: 2

Fatigue

Overweight

Cardiovascular

Insulin resistance

Quality of life

QLQ-C30, SF-36

Dual X-ray absorptiometry: total lean body mass, regional lean mass: upper limb, lower limb, appendicular skeletal muscle total fat mass, trunk fat mass, and percentage body fat, Blood samples: total cholesterol, LDL, HDL, triglycerides, CRP 400 m walk

Blood samples: Insulin + glucose

EORTC-QLQ-C30; SF-36

Bourke [14]

Int: 25

Con: 25

Total: 50

Int: 71.3

Con: 72.2

Non localized PCa who receiving ADT ≥ 6 monthsSupervised + unsupervised aerobic + resistance exercise

Duration: 12 Frequency: Resistance + aerobic: week 1–6: 1; 7–12:2x

Eating seminars: 1x

Fatigue

Overweight

Insulin

resistance Quality of life

FACT-F

BMI; weight; waist-to-hip ratio Blood biomarkers: insulin; IGF-1

FACT-P; FACT-G

Cormie [15]

Int: 29

Con: 28

Total: 57

Int: 69.5

Con: 70.1

Locally PCa, on ADT ≥ 2 months and remained hypogonadal for ≥ 6 monthsSupervised aerobic + resistance exercise

Duration: 12

Frequency: 2

Libido and sexual

function

Quality of life

QLQ-PR25

SF-36

Hvid [16]

Int: 10

Con: 9

Total: 19

Int: 67.8

Con: 68.5

PCa with ADT > 3 months

Control group: healthy males

Supervised endurance

Exercise

Duration: 12

Frequency: 3

Overweight

Cardiovascular

Insulin resistance

Dual x-ray absorptiometry: body lean mass, fat mass, trunk fat mass MR: femoral to liver distance, visceral fat mass, skin fat mass, intermuscular adipose tissue Tissue samples: m. vastus lateralis

Blood biomarkers: total cholesterol, LDL, HDL, triglycerides

VO2 Max

OGTT Euglycemic–hyperinsulinemic clamp

Blood samples: glucose, insulin

Glucose kinetics calculations

Santa Mina [17]

Aer: 32

Res: 34

Total: 66

Aer: 72.1

Res: 70.6

PCa currently

receiving ADT ≥ 12 months

Supervised and unsupervised aerobic or resistance exercise

Duration: 26

Frequency

Total: 3–5

Supervised: 1 × 2 week

Fatigue

Overweight

Gynecomastia

Cardiovascular

Quality of life

FACT-F

BMI, Body fat, waist circumference, body fat: Skinfolds:

chest, abdomen + thigh Chest skinfold thickness VO2 max

FACT-P; PORPUS

Vitolins [18]

Soy: 30

Ven: 30 V + S: 30

Con: 30

Total:120

Soy: 71

Ven: 67

V + S: 69

Con: 67

Locally advanced or metastatic PCa on ADT and having hot flushes

Soy protein: 20 g

Venlafaxine

Duration: 12

Frequency: daily

Hot flashes

Quality of life

HFSSS

FACT-P; FACT-G

Walker [19]

Int: 20

Con: 20

Total: 40

NRPCa on ADT

Education booklet on side effects

Educational review survey

NALibido

PAIR inventory: DAS scale

Sexual activity

Bourke [20]

Int: 50

Con: 50

Total: 100

Int: 71

Con: 71

Locally advanced or metastatic PCa, previously on ADT ≥ 6 months and planned long term on ADT

Aerobic + resistance

Exercise + dietary advice

Duration: 12

Frequency

Resistance: week 1–6: 2x; 7–12: 1x

Aerobic: week 1-6: 1; 7–12: 2x

Dietary: 1 × 2 weeks

Fatigue

Overweight

Cardiovascular

Quality of life

FACT-F

BMI; weight

Systolic blood pressure, aerobic exercise tolerance

FACT-P

Uth [21]

Int: 29

Con: 28

Total: 57

Int: 67.1

Con: 66.5

Advanced or locally advanced PCa with ADT or surgical castration ≥ 6 monthsSupervised football training

Duration: 12

Frequency: week 1–8: 2

week 9–12: 3

Overweight

Cardiovascular

Dual X-ray absorptiometry: lean body mass, android, gynoid total body fat mass: BMI; waist circumference; hip circumference

VO2 max: 4-min walking test; incremental test to exhaustion Pulmonary gas exchange measurements

Heart rate monitors

Winters- stone [22, 23]

Int: 29

Con: 22

Total: 51

Int: 69.9

Con: 70.5

Localized or metastatic PCa currently receiving ADT

Int: Supervised + unsupervised resistance exercise

Cont: Stretching

Duration: 52

Frequency: 3

Fatigue

Overweight

Insulin resistance

Quality of life

SCFS BMI

Dual X-ray absorptiometry: Fat mass; Bone-free lean mass; trunk

fat mass

Blood biomarkers: insulin; IGF-1

LLFDI

Cormie [24]

Int: 32

Con: 31

Total: 63

Int: 69.6

Con: 67.1

PCa within first 10 days on ADT and anticipated to remain on ADT ≥ 3 monthsSupervised aerobic + resistance exercise

Duration: 12

Frequency: 2

Fatigue

Overweight

Cardiovascular

Osteoporosis

Libido

Insulin resistance

Depression

Quality of life

FACIT-fatigue

Dual X-ray absorptiometry: body lean mass, fat mass, appendicular lean mass, trunk fat mass, visceral fat mass

Blood biomarkers: CRP VO2 max: 400-m walk test RR: brachial

Dual X-ray absorptiometry: BMD: hip, lumbar spine, whole body Blood biomarkers: alkaline phosphatase, P1NP, N-telopeptide, N-telopeptide/creatinine ratio, vitamin D

QLQ-PR25

Blood biomarkers: Insulin, glucose

BSI-18

QLQ-PR25; SF-36

Nilsen [25]

Int: 28

Con: 30

Total: 58

Int: 66

Con: 66

Locally advanced PCa receiving RT after neo-adjuvant ADT for 6 months and adjuvant ADT 9–36 monthsSupervised resistance exercise

Duration: 16

Frequency: 3

Overweight

Fatigue

Osteoporosis

Cardiovascular

Quality of life

Dual x-ray absorptiometry: lean body mass, Regional LBM: (trunk, lower extremities, upper extremities, appendicular skeletal mass), fat mass, fat percentage, body mass, BMI

EORTC- QLQ-C30

Dual X-ray absorptiometry: BMD: total, total lumbar spine, hip, trochanter and femoral neck Shuttle walk test

EORTC-QLQ-C30

O’neill [26]

Int: 47

Con: 47

Total: 94

Int: 69.7

Con: 69.9

PCa treated ADT for ≥ 6 months and planned to continue for ≥ 6 months or commencing to start ≥ 6 monthsAerobic exercise + dietary advice

Duration: 26

Frequency: Walking: 5

Overweight

Fatigue

Cardiovascular

Quality of life

Weight, BMI, fat mass, lean muscle mass, waist-to-hip ratio, mid-upper arm muscle area

Fat mass: Skinfold thickness FSS

400-m walk test FACT-P; PSS

Stefanopoul ou [27]

Int: 33

Con: 35

Tot: 68

Int: 68.0

Con: 68.7

Localized or metastatic

PCa undergoing ADT

CBT bookletDuration: 4

Hot

Flushes

Depression

Quality of life

HFNS

HADS

EORTC-QLQ-C30; EORTC- QLQ-PR25

Gilbert [28]

Int: 25

Con: 25

Total: 50

Int: 70.1

Con: 70.4

PCa receiving ADT ≥

6 months + radiotherapy

Supervised + unsupervised aerobic, balance, resistance exercise + Dietary advice: healthy-eating seminars

Duration 12

Frequency: Training: 3 Diet: 1 × 2 week

Overweight

Cardiovascular

BMI, weight

Blood biomarkers: total cholesterol, LDL, HDL, triglycerides

RR: Brachial artery FMD, GTN-arterial dilatation

VO2 max: Exercise tolerance: walking test

Nilsen [29]

Int: 16

Con: 15

Total: 31

Int: 66

Con: 65

Locally advanced PCa receiving RT after neo-adjuvant ADT for 6 months and adjuvant ADT 9-36 monthsSupervised resistance exercise

Duration: 16

Frequency: 3

OverweightMuscles biopsies m. Vastus lateralis: protein concentrations, HSP70, Alpha B-crystalline, HSP27, HSP27, HSP60, C OXIV, Citrate synthase Ubiquitin
Nilsen [30]

Int: 12

Con: 11

Total: 23

Int: 67

Con: 64

Locally advanced PCa receiving RT after neo-adjuvant ADT for 6 months and adjuvant ADT 9–36 monthsSupervised resistance exercise

Duration: 16

Frequency: 3

OverweightMuscle biopsies m. Vastus lateralis: histology, muscle fiber CSA, myonuclei, satellite cells, protein concentrations
Sajid [31]

EXCAP: 6

Wii-fit: 8

Con: 5

Total: 19

EXCAP: 75.7

Wii-fit

77.5

Con: 71.8

PCa with ADT, ADT combined with RT

EXCAP: Unsupervised aerobic exercise + resistance exercise

Wii-fit: Multi- component exercise on WII

Duration: 6

Frequency: 5

Fatigue Overweight

SPPB

Dual X-ray absorptiometry: body fat mass, body lean mass, skeletal muscle mass

Uth [32]

Int: 29

Con: 28

Total: 57

Int: 67.1

Con: 66.5

Locally advanced or metastatic PCa undergoing ADT for ≥ 6 monthsSupervised football exercise

Duration: 32 Frequency: week 1–: 2

week 9–12: 3

week 12–32: 2

Overweight

Osteoporosis

Dual X-ray absorptiometry: body lean mass, fat mass, percentage fat mass, Dual x-ray absorptiometry: BMD: total hip, femoral, lumbar spine, Blood samples: P1NP, osteocalcin, CTX
Uth [33]

Int: 29

Con: 28

Total: 57

Int: 67.1

Con: 66.5

Locally advanced or metastatic Pca undergoing ADT for ≥ 6 months

Supervised football

exercise

Duration: 12

Frequency:

wk 1-8: 2

wk 9-12: 3

Osteoporosis

Dual X-ray absorptiometry

BMC: total body, legs

BMD: total body, legs

Blood biomarkers: CTX, P1NP, osteocalcin

Kim [34]

Int: 26

Con: 25

Total: 51

Int: 70.5

Con: 71.0

PCa Stage I to III

receiving ADT

Unsupervised strength training + resistance exercise

Duration: 26

Frequency: 3-5

Osteoporosis

Quality of life

Dual x-ray absorptiometry: total BMD, regional BMD: Total hip, femur neck, lumbar spine, Blood samples: bs-ALP, Ntx

FACT-P

Taaffe [35]

ILRT: 58

ART: 54

Con: 51 Total:163

ILRT:68. 9

ART: 69

Con: 68.4

PCa with

ADT exposure ≥ 2 months, anticipated to

receive ADT following

12 months

Supervised impact + resistance exercise (ILRT)

Supervised + unsupervised aerobic + resistance exercise (ART)

Duration: 52 Frequency: ILRT + AER: 2Fatigue Cardiovascular

EORTC-QLQ-C30; SF-36

400 m walk

Wall et al. [36]

Int: 50

Con: 47

Total: 97

Int: 69.1

Con: 69.1

Localized PCa on ADT for ≥ 2 monthsSupervised and unsupervised aerobic + resistance exercise

Duration: 26

Frequency: 2

Overweight

Cardiovascular

Insulin resistance

Dual X-ray absorptiometry: lean body mass, fat mass, trunk fat mass, percentage body fat, appendicular fat mass, weight

Blood biomarkers: CRP

Respiratory gas analysis: fat oxidation, carbohydrate oxidation

Blood samples: LDL; HDL; cholesterol, triglycerides VO2Max; RR: brachial Applanation tonometry: arterial stiffness, aortal blood pressure Carotid-to-radial pulse-wave Blood biomarkers: Insulin: Hba1c, glucose

Dawson [37]

Int: 13

Con: 19

Total: 32

Pro: 68.6

Con: 66.3

PCa with ADTSupervised resistance training

Duration: 12

Frequency: 3

Fatigue Overweight

Cardiovascular

Insulin resistance

Depression Quality of life

BFI

Dual X-ray: appendicular skeletal mass, lean body mass, fat mass, percentage body fat, waist circumference

Systolic blood pressure, diastolic blood pressure

Blood biomarkers: Glucose CES-D

FACT-G; FACT-P

RCTs randomized controlled trials; Int intervention group, Con control group, PCa prostate cancer, ADT androgen deprivation therapy, RT radiotherapy, Ven/V venlafaxine, Soy/S soy protein, physical examinations, BMI body mass index, LBM lean body mass, BMD bone mineral density, BMC bone mineral content, PPB positive pressure, breathing, RR blood pressure, OGTT oral glucose tolerance test, VO2 max maximal oxygen consumption, FMD flow-mediated dilatation, GTN-arterial dilatation glyceryl trinitrate-arterial dilatation

Blood biomarkers IGF-1: Insulin Growth Factor-1, IGFBP: Insulin-Like Growth Factor-Binding Peptide, IGFBP-1: Insulin-Like Growth Factor-Binding Peptide-1, IGFBP-3: Insulin-Like Growth Factor-Binding Peptide-3, Hba1c: Glycosylated Hemoglobin type A1c, LDL: Low Density Lipoprotein, HDL: High Density Lipoprotein, CRP: C-Reactive Protein, CTX: Cyclophosphamide, P1NP: Procollagen Type 1, bs-ALP: bone-specific Alkaline Phosphatase, NTX: N-Telopeptide of type I collagen

Questionnaires CES-D: Center for Epidemiologic Studies Depression scale, HADS: Hospital Anxiety and Depression Scale, DAS scale: Depression, Anxiety and Stress scale, BFI: Big Five Inventory, BSI-18: Brief Symptom Inventory 18, FSS: Fatigue Severity Scale, FACT-P: Functional Assessment of Cancer Therapy-Prostate; FACT-G: Functional Assessment of Cancer Therapy General; FACT-F: Functional Assessment of Cancer Therapy Fatigue POMS: Profile Of Mood Status; EIFI-exhaustion: The Exercise-Induced Feeling Inventory EORTC-QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, EORTC-QLQ-PR25: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Prostate-Specific 25-item, SF-36: short-form health survey (36), EPIC: Expanded Prostate Cancer Index, HFSS: Hot Flashes Severity Score, HFNS: Hot Flushes and Night Sweats, HFSSS: Hot Flushes Severity Symptom Score, PAIR inventory: Personal Assessment of Intimacy in Relationships, SPPB: Short Physical Performance Battery, IIEF: International Index of Erectile Function, WSFS: Watts Sexual Functioning Scale; PORPUS: Patient-Oriented Prostate Utility Scale, PSS: Perceived Stress Scale, LLFDI: Late Life Function and Disability Instrument, STAI: State-Trait Anxiety Inventory

Study characteristics of the included studies Int: 82 Con: 73 Total: 155 Int: 68.2 Con: 67.7 Local and advanced PCa receiving ADT ≥ 3 months Duration: 12 Frequency: 3 Fatigue Overweight Quality of life FACT-F BMI, waist circumference, skinfolds thickness FACT-P Life: 46 Educ: 51 Con: 37 Total: 134 Lifestyle activity program Educational support program Duration 24 Frequency: week 1–16: 1 4 week: 2 Overweight Depression Quality of life BMI: Waist and hip circumferences, waist-hip ratio CES-D SF-36, STAI Soy: 20 Con: 19 Total 39 Soy: 69.2 Con: 69.0 Duration: 12 Frequency: 7 Fatigue Libido and sexual function Hot flushes Quality of life SF-36 IIEF, WSFS Blatt-Kupperman scale SF-36 Int: 53 Con: 47 Total: 100 Int: 67.2 Con: 68 Duration: 16 Frequency: 3–5 Fatigue Overweight Cardiovascular Libido Depression Quality of life FSS BMI, waist-to-hip ratio RR EPIC CES-D EORTC-QLQ-C30, EPIC Int: 29 Con: 28 Total: 57 Int: 69.5 Con: 70.1 Duration: 12 Frequency: 2 Fatigue Overweight Cardiovascular Insulin resistance Quality of life QLQ-C30, SF-36 Dual X-ray absorptiometry: total lean body mass, regional lean mass: upper limb, lower limb, appendicular skeletal muscle total fat mass, trunk fat mass, and percentage body fat, Blood samples: total cholesterol, LDL, HDL, triglycerides, CRP 400 m walk Blood samples: Insulin + glucose EORTC-QLQ-C30; SF-36 Int: 25 Con: 25 Total: 50 Int: 71.3 Con: 72.2 Duration: 12 Frequency: Resistance + aerobic: week 1–6: 1; 7–12:2x Eating seminars: 1x Fatigue Overweight Insulin resistance Quality of life FACT-F BMI; weight; waist-to-hip ratio Blood biomarkers: insulin; IGF-1 FACT-P; FACT-G Int: 29 Con: 28 Total: 57 Int: 69.5 Con: 70.1 Duration: 12 Frequency: 2 Libido and sexual function Quality of life QLQ-PR25 SF-36 Int: 10 Con: 9 Total: 19 Int: 67.8 Con: 68.5 PCa with ADT > 3 months Control group: healthy males Supervised endurance Exercise Duration: 12 Frequency: 3 Overweight Cardiovascular Insulin resistance Dual x-ray absorptiometry: body lean mass, fat mass, trunk fat mass MR: femoral to liver distance, visceral fat mass, skin fat mass, intermuscular adipose tissue Tissue samples: m. vastus lateralis Blood biomarkers: total cholesterol, LDL, HDL, triglycerides VO2 Max OGTT Euglycemic–hyperinsulinemic clamp Blood samples: glucose, insulin Glucose kinetics calculations Aer: 32 Res: 34 Total: 66 Aer: 72.1 Res: 70.6 PCa currently receiving ADT ≥ 12 months Duration: 26 Frequency Total: 3–5 Supervised: 1 × 2 week Fatigue Overweight Gynecomastia Cardiovascular Quality of life FACT-F BMI, Body fat, waist circumference, body fat: Skinfolds: chest, abdomen + thigh Chest skinfold thickness VO2 max FACT-P; PORPUS Soy: 30 Ven: 30 V + S: 30 Con: 30 Total:120 Soy: 71 Ven: 67 V + S: 69 Con: 67 Soy protein: 20 g Venlafaxine Duration: 12 Frequency: daily Hot flashes Quality of life HFSSS FACT-P; FACT-G Int: 20 Con: 20 Total: 40 Education booklet on side effects Educational review survey PAIR inventory: DAS scale Sexual activity Int: 50 Con: 50 Total: 100 Int: 71 Con: 71 Aerobic + resistance Exercise + dietary advice Duration: 12 Frequency Resistance: week 1–6: 2x; 7–12: 1x Aerobic: week 1-6: 1; 7–12: 2x Dietary: 1 × 2 weeks Fatigue Overweight Cardiovascular Quality of life FACT-F BMI; weight Systolic blood pressure, aerobic exercise tolerance FACT-P Int: 29 Con: 28 Total: 57 Int: 67.1 Con: 66.5 Duration: 12 Frequency: week 1–8: 2 week 9–12: 3 Overweight Cardiovascular Dual X-ray absorptiometry: lean body mass, android, gynoid total body fat mass: BMI; waist circumference; hip circumference VO2 max: 4-min walking test; incremental test to exhaustion Pulmonary gas exchange measurements Heart rate monitors Int: 29 Con: 22 Total: 51 Int: 69.9 Con: 70.5 Int: Supervised + unsupervised resistance exercise Cont: Stretching Duration: 52 Frequency: 3 Fatigue Overweight Insulin resistance Quality of life SCFS BMI Dual X-ray absorptiometry: Fat mass; Bone-free lean mass; trunk fat mass Blood biomarkers: insulin; IGF-1 LLFDI Int: 32 Con: 31 Total: 63 Int: 69.6 Con: 67.1 Duration: 12 Frequency: 2 Fatigue Overweight Cardiovascular Osteoporosis Libido Insulin resistance Depression Quality of life FACIT-fatigue Dual X-ray absorptiometry: body lean mass, fat mass, appendicular lean mass, trunk fat mass, visceral fat mass Blood biomarkers: CRP VO2 max: 400-m walk test RR: brachial Dual X-ray absorptiometry: BMD: hip, lumbar spine, whole body Blood biomarkers: alkaline phosphatase, P1NP, N-telopeptide, N-telopeptide/creatinine ratio, vitamin D QLQ-PR25 Blood biomarkers: Insulin, glucose BSI-18 QLQ-PR25; SF-36 Int: 28 Con: 30 Total: 58 Int: 66 Con: 66 Duration: 16 Frequency: 3 Overweight Fatigue Osteoporosis Cardiovascular Quality of life Dual x-ray absorptiometry: lean body mass, Regional LBM: (trunk, lower extremities, upper extremities, appendicular skeletal mass), fat mass, fat percentage, body mass, BMI EORTC- QLQ-C30 Dual X-ray absorptiometry: BMD: total, total lumbar spine, hip, trochanter and femoral neck Shuttle walk test EORTC-QLQ-C30 Int: 47 Con: 47 Total: 94 Int: 69.7 Con: 69.9 Duration: 26 Frequency: Walking: 5 Overweight Fatigue Cardiovascular Quality of life Weight, BMI, fat mass, lean muscle mass, waist-to-hip ratio, mid-upper arm muscle area Fat mass: Skinfold thickness FSS 400-m walk test FACT-P; PSS Int: 33 Con: 35 Tot: 68 Int: 68.0 Con: 68.7 Localized or metastatic PCa undergoing ADT Hot Flushes Depression Quality of life HFNS HADS EORTC-QLQ-C30; EORTC- QLQ-PR25 Int: 25 Con: 25 Total: 50 Int: 70.1 Con: 70.4 PCa receiving ADT 6 months + radiotherapy Duration 12 Frequency: Training: 3 Diet: 1 × 2 week Overweight Cardiovascular BMI, weight Blood biomarkers: total cholesterol, LDL, HDL, triglycerides RR: Brachial artery FMD, GTN-arterial dilatation VO2 max: Exercise tolerance: walking test Int: 16 Con: 15 Total: 31 Int: 66 Con: 65 Duration: 16 Frequency: 3 Int: 12 Con: 11 Total: 23 Int: 67 Con: 64 Duration: 16 Frequency: 3 EXCAP: 6 Wii-fit: 8 Con: 5 Total: 19 EXCAP: 75.7 Wii-fit 77.5 Con: 71.8 EXCAP: Unsupervised aerobic exercise + resistance exercise Wii-fit: Multi- component exercise on WII Duration: 6 Frequency: 5 SPPB Dual X-ray absorptiometry: body fat mass, body lean mass, skeletal muscle mass Int: 29 Con: 28 Total: 57 Int: 67.1 Con: 66.5 Duration: 32 Frequency: week 1–: 2 week 9–12: 3 week 12–32: 2 Overweight Osteoporosis Int: 29 Con: 28 Total: 57 Int: 67.1 Con: 66.5 Supervised football exercise Duration: 12 Frequency: wk 1-8: 2 wk 9-12: 3 Dual X-ray absorptiometry BMC: total body, legs BMD: total body, legs Blood biomarkers: CTX, P1NP, osteocalcin Int: 26 Con: 25 Total: 51 Int: 70.5 Con: 71.0 PCa Stage I to III receiving ADT Duration: 26 Frequency: 3-5 Osteoporosis Quality of life Dual x-ray absorptiometry: total BMD, regional BMD: Total hip, femur neck, lumbar spine, Blood samples: bs-ALP, Ntx FACT-P ILRT: 58 ART: 54 Con: 51 Total:163 ILRT:68. 9 ART: 69 Con: 68.4 PCa with ADT exposure ≥ 2 months, anticipated to receive ADT following 12 months Supervised impact + resistance exercise (ILRT) Supervised + unsupervised aerobic + resistance exercise (ART) EORTC-QLQ-C30; SF-36 400 m walk Int: 50 Con: 47 Total: 97 Int: 69.1 Con: 69.1 Duration: 26 Frequency: 2 Overweight Cardiovascular Insulin resistance Dual X-ray absorptiometry: lean body mass, fat mass, trunk fat mass, percentage body fat, appendicular fat mass, weight Blood biomarkers: CRP Respiratory gas analysis: fat oxidation, carbohydrate oxidation Blood samples: LDL; HDL; cholesterol, triglycerides VO2Max; RR: brachial Applanation tonometry: arterial stiffness, aortal blood pressure Carotid-to-radial pulse-wave Blood biomarkers: Insulin: Hba1c, glucose Int: 13 Con: 19 Total: 32 Pro: 68.6 Con: 66.3 Duration: 12 Frequency: 3 Fatigue Overweight Cardiovascular Insulin resistance Depression Quality of life BFI Dual X-ray: appendicular skeletal mass, lean body mass, fat mass, percentage body fat, waist circumference Systolic blood pressure, diastolic blood pressure Blood biomarkers: Glucose CES-D FACT-G; FACT-P RCTs randomized controlled trials; Int intervention group, Con control group, PCa prostate cancer, ADT androgen deprivation therapy, RT radiotherapy, Ven/V venlafaxine, Soy/S soy protein, physical examinations, BMI body mass index, LBM lean body mass, BMD bone mineral density, BMC bone mineral content, PPB positive pressure, breathing, RR blood pressure, OGTT oral glucose tolerance test, VO2 max maximal oxygen consumption, FMD flow-mediated dilatation, GTN-arterial dilatation glyceryl trinitrate-arterial dilatation Blood biomarkers IGF-1: Insulin Growth Factor-1, IGFBP: Insulin-Like Growth Factor-Binding Peptide, IGFBP-1: Insulin-Like Growth Factor-Binding Peptide-1, IGFBP-3: Insulin-Like Growth Factor-Binding Peptide-3, Hba1c: Glycosylated Hemoglobin type A1c, LDL: Low Density Lipoprotein, HDL: High Density Lipoprotein, CRP: C-Reactive Protein, CTX: Cyclophosphamide, P1NP: Procollagen Type 1, bs-ALP: bone-specific Alkaline Phosphatase, NTX: N-Telopeptide of type I collagen Questionnaires CES-D: Center for Epidemiologic Studies Depression scale, HADS: Hospital Anxiety and Depression Scale, DAS scale: Depression, Anxiety and Stress scale, BFI: Big Five Inventory, BSI-18: Brief Symptom Inventory 18, FSS: Fatigue Severity Scale, FACT-P: Functional Assessment of Cancer Therapy-Prostate; FACT-G: Functional Assessment of Cancer Therapy General; FACT-F: Functional Assessment of Cancer Therapy Fatigue POMS: Profile Of Mood Status; EIFI-exhaustion: The Exercise-Induced Feeling Inventory EORTC-QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, EORTC-QLQ-PR25: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Prostate-Specific 25-item, SF-36: short-form health survey (36), EPIC: Expanded Prostate Cancer Index, HFSS: Hot Flashes Severity Score, HFNS: Hot Flushes and Night Sweats, HFSSS: Hot Flushes Severity Symptom Score, PAIR inventory: Personal Assessment of Intimacy in Relationships, SPPB: Short Physical Performance Battery, IIEF: International Index of Erectile Function, WSFS: Watts Sexual Functioning Scale; PORPUS: Patient-Oriented Prostate Utility Scale, PSS: Perceived Stress Scale, LLFDI: Late Life Function and Disability Instrument, STAI: State-Trait Anxiety Inventory Table 2 shows an overview of RCTs testing mitigation strategies for ADT-induced side effects, categorized per side effect. Table 3 summarizes the quality scores of the RCTs. The quality differed between the studies. The most common source of methodological bias was a lack of proper blinding procedures. Almost one-third of the studies presented incomplete outcome data.
Table 2

Overview of RCTs testing mitigation strategies for ADT categorized per side effect

Side effectInterventionStudyOutcomesMethods to measure outcome
Quality of lifeAerobic trainingSanta Mina et al. [17]No differencePRO (FACT-P; PORPUS)
Aerobic training + dietary adviceO’neill et al. [26]Improvement in the individual functional well-being subscale (P = 0.04) measured with FACT-P at 26 weeksPRO (FACT-P; PSS)
Aerobic + Resistance trainingCulos-Reed et al. [12]No differencePRO (EORTC-QLQ-C30, EPIC)
Galvao et al. [13]Significant improvement for general health (P = 0.022), vitality (P = 0.19) and physical health score (P = 0.02) measured with SF-36 Significant improvement in role (P < 0.001), cognitive (P = 0.007), nausea (P = 0.025), dyspnea (P = 0.17) measured with QLQ-C30 after 12 weeksPRO (QLQ-C30; SF-36)
Bourke et al. [14]No differencePRO (FACT-P; FACT-G)
Cormie et al. [24]Significant improvement in social functioning (P = 0.015), mental health domains (P = 0.006) and the mental health composite score (P = 0.022) after 12 weeks measured with SF-36PRO (QLQ-PR25; SF-36)
Aerobic + resistance + dietary adviceCormie et al. [15]Significant difference in perceived general health (P = 0.022), vitality (P = 0.019); physical health composite (P = 0.02) subscales measured with SF-36 at 12 weeksPRO (SF-36)
Bourke et al. [20]Significant improvement after 12 weeks (P = 0.001), no change after 24 weeks measured with FACT-PPRO (FACT-P)
Cognitive behavioral therapyStefanopoulou et al. [27]No differencesPRO (EORTC-QLQ-C30; EORTC-QLQ-PR25)
Resistance trainingSegal et al. [9]Increase in QOL, compared with a decrease for the control group (P = 0.001) measured with FACT-P after 12 weeksPRO (FACT-P)
Taylor et al. [5]No differencesPRO (SF-36, STAI)
Santa Mina et al. [17]No differencesPRO (FACT-P; PORPUS)
Nilsen et al. [25]No differencesPRO (EORTC-QLQ-C30)
Kim et al. [34]No differencesPRO (FACT-P)
Dawson et al. [37]Significant improvement in quality of life measured with FACT-G (P = 0.048) and FACT-P (P = 0.04)PRO (FACT-G; FACT-P)
Soy proteinSharma et al. [11]No differencesPRO (SF-36)
Vitolins et al. [18]Improvements in emotional (P = 0.029) and functional subscales (P = 0.041) and in FACT-G (P = 0.025) and FACT-P total scores. (P = 0.048)PRO (FACT-P; FACT-G)
DepressionAerobic + resistance trainingCulos-Reed et al. [12]No differencesPRO (CES-D)
Santa Mina et al. [17]No differencesPRO (FACT-F)
Cormie et al. [24]No differencesPRO (BSI-18)
Cognitive behavioral therapyStefanopoulou et al. [27]No differencesPRO (HADS)
Educational support programTaylor et al. [10]No differencesPRO (CES-D)
Lifestyle activity programTaylor et al. [10]No differencesPRO (CES-D)
Resistance trainingDawson et al. [37]No differencesPRO (CES-D)
FatigueAerobic trainingSanta Mina et al. [17]No differencesPRO (FACT-F)
Aerobic training + dietary adviceO’neill et al. [26]No differencesPRO (FSS)
Aerobic + resistance trainingCormie et al. [24]Significant reduction (P = 0.042) measured with FACIT-fatiguePRO (FACIT-fatigue)
Culos-Reed et al. [12]No differencePRO (FSS)
Galvao et al. [13]Significant reduction in fatigue (P = 0.021) and increased vitality (P = 0.019) measured with SF-36 and QLQ-C30 resp.PRO (QLQ-C30, SF-36)
Santa Mina et al. [17]No differencesPRO (FACT-F)
Sajid et al. [31]EXCAP: Significant reduction (P = 0.04) measured with SPPB Wii-fit: no differencesPRO (SPPB)
Taaffe et al. [35]Significant reduction in fatigue (P = 0.005) and increased vitality (P < 0.001) measured with EORTC-QLQ-C30 and SF-36 resp.PRO (EORTC-QLQ-C30; SF-36)
Aerobic + resistance training + dietary adviceBourke et al. [14]Significant reduction at 12 weeks (P = 0.002) and 6 months (P = 0.006) measured with FACT-FPRO (FACT-F)
Bourke et al. [20]Significant reduction at 12 weeks (P < 0.001) and 6 months (P = 0.010) measured with FACT-PPRO (FACT-P)
Impact + resistance trainingTaaffe et al. [35]Significant reduction of fatigue (P = 0.005) and increased vitality (P < 0.001)PRO (EORTC-QLQ-C30; SF-36)
Resistance trainingSegal et al. [9]Significant reduction (P = 0.002)PRO (FACT-F)
Sharma et al. [11]

Significant reduction after 12 weeks (P = 0.010) and 24 weeks (P = 0.002)

Per-group analysis: significant reduction after 24 weeks (P = 0.04)

PRO (SF-36)
Santa Mina et al. [17]No differencesPRO (FACT-F)
Nilsen et al. [25]No differencesPRO (EORTC- QLQ-C30)
Dawson et al. [37]No differencesPRO (BFI)
Soy proteinSharma et al. [11]No differencesPRO (SF-36)
Decreased libido + sexual functionAerobic + resistance trainingCulos-Reed et al. [12]No difference between groups or effect over time in sexual functionPRO (EPIC)
Cormie et al. [15]Significant difference in percentage of major interest in sex (P = 0.024) and maintenance in level of sexual activity (P = 0.045) No change in any level of sexual interest or sexual functionPRO (QLQ-PR25)
Cormie et al. [24]

Significant less decline in sexual function (P = 0.028), no difference in sexual activity

Per-group-analysis over time: decline in sexual activity (P = 0.012), no change in sexual function

PRO (QLQ-PR25)
Information bookletWalker et al. [19]No significant differences. Sexual activity at baseline: 64.3% versus 38.5% (control), after 6 months: 25% versus 0% (control)PRO (PAIR inventory: DAS scale, sexual activity)
Soy proteinSharma et al. [11]No differencesPRO (IIEF, WSFS)
OverweightAerobic trainingHvid et al. [16]

Body composition: no differences Per-group analysis: reduction in BMI (P < 0.0001), weight (P < 0.0001), fat mass (P < 0.01), fat percentage (P < 0.05), trunk fat mass (P < 0.01)

Blood biomarkers: no differences

Per-group analysis: Increase in HDL over time. No differences in LDL, total cholesterol, triglycerides

Body composition and blood biomarkers
Santa Mina et al. [17]No differencesBody composition
Aerobic training + dietary adviceO’neill et al. [26]

Body composition: significant reduction (all P = 0.001), waist-to-hip ratio (P = 0.009)

No difference in lean body mass or mid-upper arm muscle area

Body composition
Aerobic + resistance trainingCulos-Reed et al. [12]

Body composition: significant reduction in waist girth (P = 0.044) and neck girth (P-0.019), no difference in BMI

Per-group analysis: no difference in BMI

Body composition
Galvao et al. [13]

Body composition: significant increase in total lean mass (P = 0.047), upper limb (P < 0.001), lower limb (P = 0.019), appendicular skeletal mass (P = 0.03). No change in weight total body fat mass trunk fat mass or percentage body fat

Blood biomarkers: Significant decrease in CRP (P = 0.008). No change in other markers

Body composition and blood biomarkers
Cormie et al. [24]

Body composition: significant reduction in appendicular lean mass (P = 0.019), whole body fat mass (P = 0.001), whole body percentage fat (P < 0.001), trunk fat mass (P = 0.008). No differences in total body mass, visceral fat mass or body lean mass

Blood biomarkers: significant reduction in HDL total cholesterol ratio (P = 0.028). No differences in other biomarkers

Body composition and blood biomarkers
Sajid et al. [31]

EXCAP: Body composition: no differences

Wii-fit: Body composition: decrease in lean mass for the Wii-fit group (P = 0.045),

Body composition
Wall et al. [36]

Body composition: increase in lean body mass (P = 0.015), decrease in total fat mass (P = 0.020), trunk fat mass (P < 0.001), body fat percentage (P = 0.001), no change in weight

Blood biomarkers: no differences

Body composition and blood biomarkers
Aerobic + resistance training + dietary adviceBourke et al. [14]No differencesBody composition
Bourke et al. [20]No differencesBody composition
Gilbert et al. [28]

Body composition: significant increase in skeletal muscle mass (P = 0.03), no difference in BMI or body fat mass

Blood biomarkers: no differences

Body composition and blood biomarkers
Educational support programTaylor et al. [10]No differencesBody composition
Football trainingUth et al. [21]

Significant increase in lean body mass (P = 0.02), no change in body fat percentage, body fat mass

Per-group analysis: significant increase in lean body mass (P = 0.02), no change in body fat percentage or body fat mass

Body composition
Uth et al. [32, 33]No differencesBody composition
Resistance exerciseUth et al. [32, 33]No differencesBody composition
Segal et al. [9]No differencesBody composition
Santa Mina et al. [17]No differencesBody composition
Winters-stone [23]

Significant reduction in total fat mass in covariance analysis (P = 0.02), not in ITT analysis

No significant change in body lean mass, percentage body fat, weight or trunk fat mass

Body composition
Nilsen et al. [25]Significant increase in LBM in lower extremities (P = 0.002) and upper extremities (P = 0.048), appendicular skeletal muscle mass (P = 0.001). No change in total, trunk lean mass, total fat mass, trunk fat mass, percentage fat mass, weight, or BMIBody composition
Nilsen et al. [29, 30]

No significant difference in mitochondrial proteins or indicators of muscle cellular stress: HSP70 B-crystallin; ubiquitin; ubiquittinated proteins

Per-group analysis: change over time in HSP70 (P = 0.03)

Muscles biopsies m. Vastus lateralis: protein concentrations, HSP70, Alpha B-crystalline, HSP27, HSP27, HSP60, COXIV, Citrate synthase Ubiquitin
Nilsen et al. [29, 30]

Significant change in total muscle fiber in favor for intervention group (P = 0.04)

Significant increase in type II fibers for intervention group (P = 0.03); no change myonuclei number

Muscle biopsies m. Vastus lateralis: histology, muscle fiber CSA, myonuclei, satelite cells, protein concentrations
Dawson et al. [37]

Significant increase in lean mass, appendicular skelet mass (P = 0.02), sacropenic index (P = 0.02), fat free mass (P = 0.04). Significant decrease in waist circumference (P = 0.01), and percentage body fat (P = 0.01). No difference in fat mass or total mass

Blood biomarkers: No difference

Body composition
Hot flushesCognitive Behavioral TherapyStefanopoulou et al. [27]

Decreased hot flashes problem rating (P = 0.001) and reduced frequency at 6 weeks (P = 0.02).

No difference at 32 weeks

PRO (HFNS)
Soy proteinSharma et al. [11]

Difference in favor of the placebo group at 12 weeks (P = 0.04). No difference at 6 weeks

Per-group analysis: no difference in vasomotor symptoms

PRO (Blatt-Kupperman scale)
Vitolin et al. [18]

No differences

Per-group analysis: significant decrease of vasomotor symptoms (P < 0.001), hot flushes severity (P < 0.001), hot flushes symptom severity score (P < 0.001)

PRO (HFSS, HFSSS)
GynaecomastiaAerobic trainingSanta Mina et al. [17]No differenceBody composition
Resistance trainingSanta Mina et al. [17]No differenceBody composition
CardiovascularAerobic trainingHvid et al. [16]

No significant difference in VO2 max (ml(O2)/min per kg), VO2max (ml(O2)/min

Per-group analysis: increase in VO2 max (ml(O2)/min per kg) (P < 0.0001), VO2 max (ml(O2)/min) (P < 0.001).

Physical test (VO2max)
No difference
Santa Mina et al. [17]No differencePhysical test (VO2max)
Aerobic training + dietary adviceO’neill et al. [26]Significant change (P = 0.001)Physical test (6-m walk test)
Aerobic + resistance trainingCulos-Reed et al. [12]

No difference

Per-group analysis: significant reduction of systolic blood pressure (P = 0.011) and diastolic blood pressure (P = 0.004)

Blood pressure
Galvao et al. [13]No differencePhysical test (400 m walk test)
Cormie et al. [24]

Significant increase in VO2 max (P = 0.004) and 400 m walk (P = 0.009)

No change in blood pressure

Physcial test (VO2 max: 400-m walk test) Blood pressure
Taaffe et al. [35]

No differences

Per-group analysis: cardiovascular fitness improved ART: P < 0.001

Physical test (400 m walk)
Wall et al. [36]

Significant increase in VO2 Max (L min) and VO2 Max (ml/kg) (P = 0.033), fat oxidation (P = 0.037)

No change in RMR, carbohydrate oxidation, peripheral systolic, diastolic RR or MAP, central diastolic RR or MAP, peripheral augmentation index, central augmentation pressure, central augmentation, index, pulse-wave velocity

Physical test (Respiratory gas analysis, VO2 Max), blood pressure, blood samples
Aerobic + resistance training + dietary adviceBourke et al. [20]

Significant improvement in aerobic exercise tolerance at 12 weeks (P < 0.001) and 6 months (P < 0.001)

No difference in systolic blood pressure

Physcial test (aerobic exercise tolerance), blood pressure
Aerobic, balance, resistance exercise + dietary adviceGilbert et al. [28]

Treadmill walk time improved at 12 and 24 weeks (P < 0.001) Difference in FMD at 12 weeks (P = 0.04). No difference in GTN dilatation, systolic blood pressure or diastolic blood

pressure

Physical test (VO2 max, exercise tolerance: walking test), blood pressure
Football trainingUth et al. [21]

No significant difference between groups

Per-group -analysis: VO2 max increased in the intervention group (1.0 ml/kg/min) P = 0.02

Physical test (VO2 max: 4-min walking test; incremental test to exhaustion, pulmonary gas exchange measurements; heart rate monitors)
Impact + resistance trainingTaaffe et al. [35]No differencesPhysical test (400 m walk)
Resistance trainingVO2max improvement (P = 0.41), also after adjustment for covariates (P = 0.38)
Santa Mina et al. [17]Significant improvement compared to control groupPhysical test (VO2 max)
Dawson et al. [37]No differencesBlood pressure
Insulin resistanceAerobic trainingHvid et al. [16]

No difference in fasting glucose, glucose AUC or insulin AUC compared to control group

Per-group analysis: significant change in fasting glucose (P < 0.05), no change in glucose AUC or insulin AUC

Physical test (VO2 Max OGTT Euglycemic– hyperinsulinemic clamp), blood biomarkers
Aerobic + resistance trainingGalvao et al. [13]No differencesBlood biomarkers
Cormie et al. [24]No differencesBlood biomarkers
Wall et al. [36]Significant change for glucose (P < 0.001). No change for Hba1c or insulinBlood biomarkers
Aerobic + resistance training + dietary adviceBourke et al. [14]No differencesBlood biomarkers
Resistance trainingWinters-stone [23]No differencesBlood biomarkers
Dawson et al. [37]No differencesBlood biomarkers
OsteoporosisAerobic + resistance trainingCormie et al. [24]No differencesBody composition, blood biomarkers
Football trainingUth et al. [32]

Bone mineral content: significant increment in total body BMC (P = 0.013), leg BMC (P < 0.001)

Bone mineral density: no differences

Blood biomarkers: significant change P1NP (P = 0.008) and osteocalcin (P = 0.002), no change in CTX

Body composition, blood biomarkers
Uth et al. [32]

Bone mineral density: significant increment in left total hip (P = 0.030), right total hip (P = 0.015), left femoral shaft (P = 0.015), right femoral shaft (P = 0.016). No difference in right femoral neck, left femoral neck, lumbar spine L2–L4

Blood biomarkers: no differences

Body composition, blood biomarkers
Resistance trainingNilsen et al. [25]No differencesBody composition
Kim et al. [34]No differencesBody composition
Table 3

Methodological quality assessment tool for randomized controlled trials

Random sequence generation (Selection bias)Allocation concealment (Selection bias)Blinding of participants and personnel (performance bias)Blinding of outcome assessment (attrition bias)Incomplete outcome data (attrition bias)Selective reporting (reporting bias)Other bias
Segal [9]2003++?++
Taylor [10]2006+++
Sharma [11]2009++++?+
Culos-Reed [12]2010+++?+
Galvao [13]2010+++++
Bourke [14]2011+?++??
Cormie [15]2013++?+++
Hvid [16]2013++
Santa Mina [17]2013?++++
Vitolins [18]2013++++
Walker [19]2013???++
Bourke [20]2014+++++
Uth [21]2014+++++
Winters-Stone [22, 23]2015??+++
Cormie [24]2015++?+++
Nilsen [25]2015+?++++
O’Neill [26]2015++++?
Stefanopoulou [27]2015++++
Gilbert [28]2016++++++
Nilsen [29]2016+?+?
Nilsen [30]2016+?+?
Sajid [31]2016+++++
Uth [32]2016++++?
Uth [33]2016++++
Kim [34]2017+++
Taaffe [35]2017++++?
Wall Dawson [36, 37]

2017

2018

+

+

+

+

+

+

+

?

+

+

Risk of bias summary for each trial included in the systematic review as evaluated by authors

+ low risk of bias; ? Some concerns are risk of bias; − high risk of bias

Overview of RCTs testing mitigation strategies for ADT categorized per side effect Significant reduction after 12 weeks (P = 0.010) and 24 weeks (P = 0.002) Per-group analysis: significant reduction after 24 weeks (P = 0.04) Significant less decline in sexual function (P = 0.028), no difference in sexual activity Per-group-analysis over time: decline in sexual activity (P = 0.012), no change in sexual function Body composition: no differences Per-group analysis: reduction in BMI (P < 0.0001), weight (P < 0.0001), fat mass (P < 0.01), fat percentage (P < 0.05), trunk fat mass (P < 0.01) Blood biomarkers: no differences Per-group analysis: Increase in HDL over time. No differences in LDL, total cholesterol, triglycerides Body composition: significant reduction (all P = 0.001), waist-to-hip ratio (P = 0.009) No difference in lean body mass or mid-upper arm muscle area Body composition: significant reduction in waist girth (P = 0.044) and neck girth (P-0.019), no difference in BMI Per-group analysis: no difference in BMI Body composition: significant increase in total lean mass (P = 0.047), upper limb (P < 0.001), lower limb (P = 0.019), appendicular skeletal mass (P = 0.03). No change in weight total body fat mass trunk fat mass or percentage body fat Blood biomarkers: Significant decrease in CRP (P = 0.008). No change in other markers Body composition: significant reduction in appendicular lean mass (P = 0.019), whole body fat mass (P = 0.001), whole body percentage fat (P < 0.001), trunk fat mass (P = 0.008). No differences in total body mass, visceral fat mass or body lean mass Blood biomarkers: significant reduction in HDL total cholesterol ratio (P = 0.028). No differences in other biomarkers EXCAP: Body composition: no differences Wii-fit: Body composition: decrease in lean mass for the Wii-fit group (P = 0.045), Body composition: increase in lean body mass (P = 0.015), decrease in total fat mass (P = 0.020), trunk fat mass (P < 0.001), body fat percentage (P = 0.001), no change in weight Blood biomarkers: no differences Body composition: significant increase in skeletal muscle mass (P = 0.03), no difference in BMI or body fat mass Blood biomarkers: no differences Significant increase in lean body mass (P = 0.02), no change in body fat percentage, body fat mass Per-group analysis: significant increase in lean body mass (P = 0.02), no change in body fat percentage or body fat mass Significant reduction in total fat mass in covariance analysis (P = 0.02), not in ITT analysis No significant change in body lean mass, percentage body fat, weight or trunk fat mass No significant difference in mitochondrial proteins or indicators of muscle cellular stress: HSP70 B-crystallin; ubiquitin; ubiquittinated proteins Per-group analysis: change over time in HSP70 (P = 0.03) Significant change in total muscle fiber in favor for intervention group (P = 0.04) Significant increase in type II fibers for intervention group (P = 0.03); no change myonuclei number Significant increase in lean mass, appendicular skelet mass (P = 0.02), sacropenic index (P = 0.02), fat free mass (P = 0.04). Significant decrease in waist circumference (P = 0.01), and percentage body fat (P = 0.01). No difference in fat mass or total mass Blood biomarkers: No difference Decreased hot flashes problem rating (P = 0.001) and reduced frequency at 6 weeks (P = 0.02). No difference at 32 weeks Difference in favor of the placebo group at 12 weeks (P = 0.04). No difference at 6 weeks Per-group analysis: no difference in vasomotor symptoms No differences Per-group analysis: significant decrease of vasomotor symptoms (P < 0.001), hot flushes severity (P < 0.001), hot flushes symptom severity score (P < 0.001) No significant difference in VO2 max (ml(O2)/min per kg), VO2max (ml(O2)/min Per-group analysis: increase in VO2 max (ml(O2)/min per kg) (P < 0.0001), VO2 max (ml(O2)/min) (P < 0.001). No difference Per-group analysis: significant reduction of systolic blood pressure (P = 0.011) and diastolic blood pressure (P = 0.004) Significant increase in VO2 max (P = 0.004) and 400 m walk (P = 0.009) No change in blood pressure No differences Per-group analysis: cardiovascular fitness improved ART: P < 0.001 Significant increase in VO2 Max (L min) and VO2 Max (ml/kg) (P = 0.033), fat oxidation (P = 0.037) No change in RMR, carbohydrate oxidation, peripheral systolic, diastolic RR or MAP, central diastolic RR or MAP, peripheral augmentation index, central augmentation pressure, central augmentation, index, pulse-wave velocity Significant improvement in aerobic exercise tolerance at 12 weeks (P < 0.001) and 6 months (P < 0.001) No difference in systolic blood pressure Treadmill walk time improved at 12 and 24 weeks (P < 0.001) Difference in FMD at 12 weeks (P = 0.04). No difference in GTN dilatation, systolic blood pressure or diastolic blood pressure No significant difference between groups Per-group -analysis: VO2 max increased in the intervention group (1.0 ml/kg/min) P = 0.02 No difference in fasting glucose, glucose AUC or insulin AUC compared to control group Per-group analysis: significant change in fasting glucose (P < 0.05), no change in glucose AUC or insulin AUC Bone mineral content: significant increment in total body BMC (P = 0.013), leg BMC (P < 0.001) Bone mineral density: no differences Blood biomarkers: significant change P1NP (P = 0.008) and osteocalcin (P = 0.002), no change in CTX Bone mineral density: significant increment in left total hip (P = 0.030), right total hip (P = 0.015), left femoral shaft (P = 0.015), right femoral shaft (P = 0.016). No difference in right femoral neck, left femoral neck, lumbar spine L2–L4 Blood biomarkers: no differences Methodological quality assessment tool for randomized controlled trials 2017 2018 + + + + + + + ? + + Risk of bias summary for each trial included in the systematic review as evaluated by authors + low risk of bias; ? Some concerns are risk of bias; − high risk of bias

Psychological side effects

Quality of life

Health-related quality of life (HRQOL) is perceived physical and mental health over time either by an individual or by a group. The influence of lifestyle interventions on the quality of life for patients on ADT was examined in 16 studies [9–15, 17, 18, 20, 23–27, 34, 36]. Ten different questionnaires were used to measure HRQOL. Some of the questionnaires are developed to examine health-related quality of life in general (STAI; SF-36; EORTC-QLQ- C30; QLQ-PR25; PSS; FACT-G; LFDI). Others are used to investigate prostatic disease-specific quality of life or aspects of quality of life (FACT-P; PORPUS; EPIC). Eleven studies investigated the effects of physical exercises, three combined physical exercises with dietary advice, and two investigated the effect of soy consumption. In four studies, a positive effect of exercise only was noted [9, 13, 24, 36]. Two out of six studies investigating the effect of resistance training found a positive effect on the health-related quality of life and in one of these studies, an improved disease-specific quality of life had been found [36]. Aerobic and resistance training combined showed a positive effect in two out of four studies [13, 24]. In these two studies, only specific domains were significantly improved. For details, see Table 2. Variable results were found when combining exercises with dietary advice. All three studies found positive effects on different aspects of quality of life [15, 20, 26]. Bourke et al. found an improvement in the prostatic disease-specific quality of life after 12 weeks of training, but this was only temporary since the effect disappeared after 24 weeks [20]. One study investigated the effect of cognitive behavioral therapy on quality of life, but failed to show an improvement. Two studies investigated the effect of soy consumption. Vitolins et al. found an improved HRQOL as well as an improved disease-specific quality of life after consumption of soy protein, while Sharma et al. failed to show any effect [11, 18].

Depression

In the treatment of PCa, ADT use is associated with depression. Five studies focused on depression [10, 12, 24, 27, 36]. Aerobic and/or resistance training failed to show a beneficial effect [12, 24, 36]. Applied cognitive behavioral therapy (CBT) for a period of four weeks did not show a beneficial effect [27]. A lifestyle activity program or an educational support program did not influence depression scores using CES-D [10].

Fatigue

Fatigue is a phenomenon, which is difficult to measure or define. Fatigue is experienced by patients receiving ADT and is associated with decreased levels of testosterone and reduction of skeletal muscle mass may contribute to fatigue. Influence of lifestyle interventions was examined in fourteen studies: ten investigated the effects of physical exercises, three combined physical exercises with dietary advice, and one investigated the effect of soy consumption [9, 11–14, 17, 20, 24–26, 31, 35, 36]. Soy consumption showed no effect [11]. Different exercise modalities yield conflicting results in relation to fatigue. Generally speaking, in half of the studies, a reduction in fatigue was noted. Combining exercises with dietary advice showed a beneficial effect in two studies [14, 20]. Another study failed to show improvement [26].

Decreased libido and sexual function

Since androgens play an essential role in maintaining sexuality, e.g., libido and erectile function, it is obvious that ADT causes a decrease in sexual activity and may result in a variety of sexual problems. Five studies investigated methods to counteract decreased libido and erectile function [11, 12, 15, 19, 24]. Aerobic and resistance exercises were examined in three studies in which contradictory findings were reported. In 2013, Cormie et al. found maintenance of major interest in sex as well as sexual activity in the exercise group. No change in sexual function was noted. In 2015, Cormie et al. reported a diminished decline in sexual function in favor of the exercise group. In per-group analysis, a decline in sexual activity was found without change in sexual function [24]. Culos-Reed et al. found no differences [12]. Patient information concerning the side effects of ADT followed by an educational partner session failed to show an effect on libido, measured by the PAIR and DAS-scores which, respectively, assess the current level of intimacy in one’s relationship and the relationship adjustment. Couples participating in the intervention were more successful at maintaining sexual activity [19]. Soy protein consumption did not influence libido or sexual function [11].

Physical side effects

Gynecomastia

Gynecomastia may develop in ADT. In one study, gynecomastia was measured by skinfold thickness and was not influenced by aerobic or resistance training [17].

Hot flushes

Hot flushes are defined as intense heat sensation, flushing, and perspiration involving face and trunk. Anxiety and palpitations may occur. ADT may induce these complaints because the decline in LH and FSH causes the release of hypothalamic catecholamines disrupting the thermoregulation center in the upper hypothalamus. CBT temporarily lowers the occurrence of hot flushes and problem rating in men [27]. Only at 6 weeks, significance was reached, and it was no longer significant at 32 weeks. Two studies examined the effect of soy consumption on hot flushes. One study found a significant decrease of ADT-associated vasomotor symptoms in the soy protein and placebo group [18]. Sharma et al. observed no change. Surprisingly, a significant difference in favor of the placebo group was found [11].

Overweight

ADT may cause metabolic effects including dyslipidemia, elevated fasting serum glucose, weight gain, and increase in fat mass. C-reactive protein (CRP) might be a marker of adverse metabolic effects. Seventeen studies reporting on exercise programs of varying duration, frequency, intensity, and degree of supervision showed conflicting results [9, 10, 12–14, 16, 17, 20–26, 28–32, 36, 37]. These articles mention aspects of body composition amounting to sixteen different items: weight, BMI, waist circumference, hip circumference, waist and neck girth, waist-to-hip ratio, mid-upper arm muscle area, total fat mass, percentage body fat, trunk fat mass, visceral fat mass, body lean mass, appendicular lean mass, and skeletal muscle mass. The effect of aerobic and/or resistance training on body composition was examined in thirteen studies. Three of these studies added dietary advice [14, 20, 28]. Beneficial effects on one or multiple items reflecting body composition were found in eight of these studies (Table 2). O’neill et al. investigated the effect of aerobic training and dietary advice and showed an improvement in body composition [26]. Two studies examined the effect of supervised football training [21, 32]. One study lasted 12 weeks, the other 32 weeks. Initially, a significant increase in lean body mass was reached after 12 weeks [21]. At 32 weeks, this effect ceased to be significant. Endurance training showed an improvement of body composition [16]. Metabolic syndrome is a clustering of at least three out of five following medical conditions: hypertension, hyperglycemia, abdominal obesity, high serum triglycerides, and a low high-density lipoproteins (HDL). Blood biomarkers reflecting these changes were examined in six studies. A decrease in HDL/total cholesterol ratio was found by Cormie et al., who investigated the effects of a 12-week program combining aerobic and resistance training [24]. An improvement in HDL was found over time after a program of endurance training [16]. No other studies reported beneficial effects. The influence of aerobic and resistance training on CRP showed contradictory results. One study found a positive effect [13], and two studies found no change [24, 36]. On microscopic level, the effect of resistance training in biopsies of the m. vastus lateralis was reported [29, 30]. An increase in total muscle fibers and type II fibers was shown [29]. Muscle atrophy is associated with reduced mitochondrial function and increased muscle cellular stress, reflected by different heat shock proteins. Only HSP70 improved significantly [30].

Cardiovascular health

Factors influencing cardiovascular health are manifold: lipid profile, blood pressure, BMI, endothelial cell function, pro-inflammatory factors, and insulin resistance. ADT has a negative impact on these factors. Besides, there is an association between ADT and the occurrence of serious cardiac arrhythmias. Eleven studies investigated the effect of physical exercise of which three studies added dietary advice [12, 13, 16–18, 24, 26, 28, 36, 37]. The results of these studies are contradictory. With respect to blood pressure, four studies found no effect on systolic or diastolic blood pressure between the groups [12, 20, 24, 28]. Culos-Reed et al. found a change in systolic and diastolic blood pressure over time in the aerobic and resistance training group [12]. Using flow-mediated dilatation (FMD) as a measure, an improvement in the exercise combined with dietary advice group was found [28]. The effect of training on maximum oxygen utilization (VO2 max) was investigated in five studies [17, 18, 24, 36, 37]. Most of these studies consisted of a mixture of aerobic and/or resistance training. Uth et al. used football training. Almost consistently, an improvement was found. Resistance training scored better in increasing cardiovascular fitness  than aerobic [17, 18]. Four studies found a significant improvement on cardiovascular fitness after physical exercises, measured by different tests [13, 26, 29, 35].

Insulin resistance

It is not completely understood how ADT therapy deregulates glucose metabolism. Possibly hypogonadism, secondary to obesity, alters fatty acid metabolism or changes in skeletal muscle may play a role. The influence of exercise on insulin resistance was measured in seven studies [13, 14, 16, 22–24, 36, 37]. One study added dietary advice. A glucose-lowering effect of exercise was shown in two studies [16, 36]. Wall et al. showed an improvement for glucose metabolism in combined aerobic and resistance training [36]. Hvid et al. investigated the effect of endurance training on insulin resistance in men on ADT compared to healthy males and found a difference in fasting glucose over time in the per-group analysis [16]. Using the oral glucose tolerance test (OGTT), no differences over time were found between the groups with regard to fasting glucose, fasting insulin, glucose AUC, and insulin AUC [16]. Biomarkers: IGF-1, insulin, IFGBP-1 and IGFBP-3, and HBA1c failed to show a difference in any of the studies.

Osteoporosis

Osteoporosis is a major concern in men undergoing ADT therapy, especially with prolonged use. Five studies investigated the effect of exercise modalities on osteoporosis [24, 25, 32–34]. We were unable to find any studies focusing on dietary advice. Dual x-ray absorptiometry (DEXA-scan) was used in all studies in order to examine bone mineral density (BMD) and bone mineral content (BMC). Blood biomarkers were examined in four studies. Biomarkers were alkaline phosphatase, P1NP, N-telopeptide, N-telopeptide/creatinine ratio, vitamin D, osteocalcin, CTX, NTX, and BS-ALP. Only Uth was able to show a significant improvement in different markers of osteoporosis. He found an increment in BMC after 12 weeks of supervised football training [33]. Initially, BMD remained unchanged after 12 weeks of training [33], whereas after 32 weeks, an increase in BMD was found in the total hip and femoral shaft [32]. P1NP and osteocalcin were the only bone formation markers that showed a significant change. After 12 weeks, there was an increase in these markers [32] After prolonged training (32 weeks), this increase no longer was significant [32].

Discussion

This study focuses on lifestyle interventions to reduce the deleterious side effects of ADT. Twenty-nine RCTs reported the effect of different lifestyle interventions. The effect of exercises in different modalities and intensities was studied including measures such as dietary advice, self-education, CBT, or educational support program. We excluded therapies like prescribing calcium and vitamin D. Regarding psychological effects, contradictory results were found. Many different questionnaires were used to examine the effect of lifestyle interventions on HRQOL, which make it hard to compare different outcomes and therefore it is difficult to make a straightforward conclusion about the effect of certain interventions. Combining exercise with diet seems to have the most beneficial effects on HRQOL; all studies regarding this combination showed a significant improvement [15, 20, 26]. Soy protein consumption was found in only one study to have a beneficial effect. An earlier study found that ADT use conferred a 41% increased risk of depression [38]. In this review, we were unable to find any difference in the occurrence of depression after applying lifestyle interventions, whereas in two studies an improvement of QOL was noted in absence of improvement of depression score [24, 37]. Tentative explanations for these outcomes can be the following. Both studies used different questionnaires to score quality of life and the occurrence of depression, making it difficult to compare them. In our review, we only noted the truly significant findings, but in the study of Cormie, where an improvement in various subscales of QOL was observed, a borderline significance was found in the depression score with a P value of 0054; this might be interpreted as a trend in improvement of physiological well-being [24]. There were many different tools used to examine fatigue. Some used general questionnaires, and others applied prostate-specific tools (FACT-F) [9, 14, 17, 20, 24]. Although there was a lack in using a common tool, different lifestyle interventions reduced fatigue and increased vitality. All studies used in this review examined physical exercises, sometimes combined with dietary advice. However, no attention was given to other lifestyle adjustments, such as smoking, alcohol use, or a balanced diet. With regard to libido and sexual function, a possible beneficial effect of aerobic and resistance training was found [15, 24]. It is noteworthy that consuming soy protein did not have any effect [11]. Considering the age group for which ADT therapy is applied, we can expect a general natural decline of libido and sexual function. Gynecomastia may very well occur after weight gain. Only one author reported on this subject [17]. This might reflect a disbelief in the effect of lifestyle changes on gynecomastia. A variety of medical therapies exist such as radiation therapy or lipolysis [39]. Two strategies were examined to reduce vasomotor symptoms. Although soy proteins appears to be successful in treating hot flushes in postmenopausal women [40], in men on ADT, they are unsuccessful. CBT appears to be helpful in managing hot flushes. Limitations of this study were the small sample size and short period of self-guided therapy. Further research might look into additional variables such as caffeine intake and other specific health problems. In this study, we divided the metabolic changes into three subcategories: overweight, insulin resistance, and cardiovascular health. These categories are interrelated. Concerning insulin resistance, studies failed to show a difference between men with ADT undergoing physical exercises or not, when measured by fasting glucose. Endurance training, however, showed no differences in OGTT between men on ADT undergoing exercises versus healthy men [16]. No trial used the novo diabetes mellitus as an outcome. Overweight was examined in 17 studies. All studies investigated the effect of exercise, and four studies added nutritional advice. Evidence was found that solely exercise or exercise combined with nutritional advice may decrease overweight. The influence of a dietary advice only on obesity hasn’t been investigated. Earlier studies showed the major impact of an appropriate diet in the prevention of obesity in the healthy old male population [41]. Considering osteoporosis, one study suggests that regularly practicing football may mitigate ADT-induced decline in BMD. However, aerobic or resistance training failed to show this decline. Future studies should investigate the effects of different exercise modalities. National osteoporosis foundation recommends a daily calcium intake of 1200 mg and supplemental vitamin D of 800–1000 IU to maintain bone health [42]. In this review, there was not one study, which focused on an adequate intake as described above. As mentioned earlier, we did not include RCTs in which calcium and Vitamin D were prescribed. A systematic review conducted in 2012, which investigated the effect of calcium and vitamin D suppletion in men with PCa using ADT showed conflicting effects [43]. It would be interesting to conduct studies in which dietary advice is given to promote sufficient intake of calcium and vitamin D and investigate this effect on the development of osteoporosis in patients on ADT. A number of limitations in this review must be considered. Firstly, we focused on two databases, PubMed and Medline, since these two are the most widely used and recognized. Secondly, there was substantial heterogeneity in life style interventions, in which some interventions were investigated frequently, while other interventions only once. This makes it impossible to compare the effects of different strategies and draw conclusions about the efficacy of these interventions. Additionally, we did not investigate the effect of duration of exercise, dietary advice, or other behavioral components. There was a variety in quality of the different RCTs. Especially, the prevention of performance bias was often inadequate, due to the fact it was impossible to blind participants following lifestyle programs. Despite these limitations, evidence suggests that lifestyle interventions may have a beneficial effect on ADT-mediated side effects.

Conclusions

Adverse effects of ADT are manifold as well as the various lifestyle interventions aimed to alleviate these side effects. Physical exercises demonstrated to have a mainly positive effect on cardiovascular health. Contradictory results were found regarding quality of life, libido, fatigue, insulin resistance, overweight, and osteoporosis. No effect was found regarding depression and gynecomastia. Regarding dietary advice, soy protein showed no beneficial effect on libido or fatigue. No other studies allowed conclusions on dietary advice solely. A positive effect was shown with CBT on the occurrence of hot flushes. Other behavioral components failed to show a significant effect regarding side effects. Further research is necessary to identify the most effective interventions for the individual patient.
  31 in total

1.  Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.

Authors:  Thine Hvid; Kamilla Winding; Anders Rinnov; Thomas Dejgaard; Carsten Thomsen; Peter Iversen; Klaus Brasso; Kari J Mikines; Gerrit van Hall; Birgitte Lindegaard; Thomas P J Solomon; Bente K Pedersen
Journal:  Endocr Relat Cancer       Date:  2013-08-19       Impact factor: 5.678

2.  Active for Life After Cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients.

Authors:  Cindy L Carmack Taylor; Carl Demoor; Murray A Smith; Andrea L Dunn; Karen Basen-Engquist; Ingrid Nielsen; Curtis Pettaway; Rena Sellin; Pamela Massey; Ellen R Gritz
Journal:  Psychooncology       Date:  2006-10       Impact factor: 3.894

Review 3.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authors:  Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; Filiberto Zattoni; Nicolas Mottet
Journal:  Eur Urol       Date:  2013-11-12       Impact factor: 20.096

4.  Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention.

Authors:  S Nicole Culos-Reed; John W Robinson; Harold Lau; Lynette Stephenson; Melanie Keats; Steve Norris; Greg Kline; Peter Faris
Journal:  Support Care Cancer       Date:  2009-07-16       Impact factor: 3.603

5.  Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.

Authors:  Daniel A Galvão; Dennis R Taaffe; Nigel Spry; David Joseph; Robert U Newton
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

6.  Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.

Authors:  Roanne J Segal; Robert D Reid; Kerry S Courneya; Shawn C Malone; Matthew B Parliament; Chris G Scott; Peter M Venner; H Arthur Quinney; Lee W Jones; Monika E Slovinec D'Angelo; George A Wells
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

7.  Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial.

Authors:  P Cormie; R U Newton; D R Taaffe; N Spry; D Joseph; M Akhlil Hamid; D A Galvão
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-01-15       Impact factor: 5.554

Review 8.  Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

Authors:  Lockwood G Taylor; Steven E Canfield; Xianglin L Du
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

9.  Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.

Authors:  Preetika Sharma; Amy Wisniewski; Milena Braga-Basaria; Xiaoqiang Xu; Mary Yep; Samuel Denmeade; Adrian S Dobs; Theodore DeWeese; Michael Carducci; Shehzad Basaria
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

10.  Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.

Authors:  Mara Z Vitolins; Leah Griffin; W Vic Tomlinson; Jacqueline Vuky; Paul T Adams; Dawn Moose; Bart Frizzell; Glenn J Lesser; Michelle Naughton; James E Radford; Edward G Shaw
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

View more
  3 in total

1.  Health-related quality of life in long-term Caribbean prostate cancer survivors: comparisons with prostate cancer-free men.

Authors:  Maria D Jackson; Evelyn Walker; Marshall K Tulloch-Reid
Journal:  Qual Life Res       Date:  2022-07-28       Impact factor: 3.440

2.  Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study.

Authors:  Myung Soo Kim; Seung Il Jung; Ho Seok Chung; Eu Chang Hwang; Dongdeuk Kwon
Journal:  Prostate Int       Date:  2020-11-20

3.  Randomised controlled trial to investigate the effectiveness of the symptom management after radiotherapy (SMaRT) group intervention to ameliorate lower urinary tract symptoms in men treated for prostate cancer.

Authors:  Sara Faithfull; Jane Cockle-Hearne; Agnieszka Lemanska; Sophie Otter; Simon S Skene
Journal:  Support Care Cancer       Date:  2021-12-21       Impact factor: 3.359

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.